SCHEMBL963144

SCHEMBL963144

CC(C)(C)[Si](C)(C)OC[C@H]1CCC(=O)N1CC(N)=S

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.32
DUT P33316 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL959880 0.89 FKBP1A (0.34) FKBP1ADUT
SCHEMBL28523662 0.85 FKBP1A (0.35) FKBP1ADUT
SCHEMBL3750168 0.85 FKBP1A (0.35) FKBP1ADUT
SCHEMBL24795958 0.82 TP53 (0.38) FKBP1ADUT
SCHEMBL1401064 0.82 TP53 (0.38) FKBP1ADUT
SCHEMBL8708692 0.81 FKBP1A (0.35) FKBP1ADUT
SCHEMBL24795965 0.81 DUT (0.33) DUT
SCHEMBL21389332 0.81 DUT (0.33) DUT
SCHEMBL28526467 0.81 DUT (0.33) DUT
SCHEMBL24795959 0.81 PDK2 (0.41) FKBP1ADUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501793-B2 Blood flow promoters for cauda equina tissues ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-06 US disclosed
US-20110015238-A1 BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
US-7833995-B2 Blood flow promoters for cauda equina tissues ONO PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20070129327-A1 Blood flow promoters for cauda equina tissues ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US disclosed
EP-1707208-A1 BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES ONO PHARMACEUTICAL CO., LTD. (JP) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129327-A1 Blood flow promoters for cauda equina tissues PTGFR, PTGIS, PTGIR FKBP1A 1008/4885DUT 1245/4885
US-20110015238-A1 BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES PTGFR, PTGIS, PTGIR FKBP1A 1008/4885DUT 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.